Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730845 | 1.00 | HCAR2 (0.55) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL26699378 | 0.81 | HCAR2 (0.55) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL1870774 | 0.81 | HCAR2 (0.55) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL212257 | 0.81 | HCAR2 (0.55) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL2050034 | 0.80 | ALDH1A1 (0.55) | HCAR2ALDH1A1ALOX15CYP2D6PAM | |
| Glutaconate SCHEMBL31023324 | 0.78 | ALDH1A1 (0.52) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL28645015 | 0.77 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL46377 | 0.77 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL10534314 | 0.77 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL9217310 | 0.77 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4584243-B1 | CROSSLINKERS | HEMOTEQ AG (DE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4626968-A1 | BINDER COMPOSITIONS AND USE THEREOF | Nilo Limited (NZ) | 2025-10-08 | — | — | EP | disclosed |
| EP-4584245-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584243-A1 | CROSSLINKERS | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584244-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250223446-A1 | BINDER COMPOSITIONS AND USE THEREOF | NILO LIMITED (NZ) | 2025-07-10 | — | — | US | disclosed |
| WO-2025056813-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056815-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| EP-4223511-A1 | CARBOXYL GROUP-CONTAINING ACRYLIC RUBBER COMPOSITION AND MULTILAYER BODY | Osaka Soda Co., Ltd. (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4157605-A2 | PROCESS FOR PRODUCING SKIN/FOAM/SKIN STRUCTURE WITH HIGH SURFACE FINISH | TotalEnergies OneTech Belgium (BE) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022071217-A1 | CARBOXYL GROUP-CONTAINING ACRYLIC RUBBER COMPOSITION AND MULTILAYER BODY | 株式会社大阪ソーダ | 2022-04-07 | — | — | WO | disclosed |
| US-20190156919-A1 | DETERMINING RELATIONSHIPS BETWEEN RISKS FOR BIOLOGICAL CONDITIONS AND DYNAMIC ANALYTES | ARIVALE, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170145245-A1 | WATER DISPERSIBLE, SELF-CROSSLINKABLE PREPOLYMER COMPOSITION | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9567311-B2 | Water dispersible, self-crosslinkable prepolymer composition | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20140378607-A1 | WATER DISPERSIBLE, SELF-CROSSLINKABLE PREPOLYMER COMPOSITON | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| CN-101076534-B | Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the initiator, and polymer | OTSUKA CHEMICAL CO LTD | 2011-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378607-A1 | WATER DISPERSIBLE, SELF-CROSSLINKABLE PREPOLYMER COMPOSITON | COASY, ABHD6, HACL2 | HCAR2 444/4885NFE2L2 4066/4885KEAP1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.